I always will start with diet and exercise
Cardiovascular and Renal Outcomes With Efpeglenatide in Type 2 Diabetes
(2021) of the CVOTs found that the GLP-1 RAs are associated with a significant 14% relative risk reduction in terms of major adverse cardiovascular events (MACE, a standard 3-component composite endpoint) (hazard ratio [HR] 0.86
August 1, 2025: Possible New Legal Options For People Suffering From Blindness Related to Ozempic A growing body of research shows that Ozempic and other GLP-1 drugs can increase the risk of a type of vision loss called NAION (non-arteritic anterior ischemic optic neuropathy)
Priority research needs include large-scale randomized controlled trials to establish efficacy and safety, dose-ranging studies to optimize treatment protocols, long-term safety studies particularly regarding cancer risk, and comparative effectiveness research with established therapies
Jul 15, 2025 The One Big Beautiful Bill was signed into law on July 4th